Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding [0.03%]
低出血风险肿瘤相关静脉血栓栓塞症患者的利伐沙班和阿哌沙班的对比研究
Kimberly Snow Caroti,Cecilia Becattini,Marc Carrier et al.
Kimberly Snow Caroti et al.
This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated ve...
A Combination of Ex Vivo and In Vivo Strategies for Evaluating How Much New Oral Anticoagulants Exacerbate Experimental Intracerebral Bleeding [0.03%]
体外和体内策略的结合评估新型口服抗凝药物加重实验性脑内出血的潜力
Juliana R P Ferreira,Isabela D Sucupira,Gabriella M C Carvalho et al.
Juliana R P Ferreira et al.
Background Intracerebral hemorrhage is the most serious complication of anticoagulant therapy but the effects of different types of oral anticoagulants on the expansion of these hemorrhages are still unclear. Clinical studies have revealed ...
The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome [0.03%]
利妥昔单抗对抗磷脂综合征患者抗磷脂滴度的影响
Kimberley Youkhana,Hilary Heiling,Allison Deal et al.
Kimberley Youkhana et al.
Potential for a Virtual Care Model in the Perioperative Management of Anticoagulant Therapy: A 5-Year Retrospective Clinic Review [0.03%]
围手术期抗凝治疗管理虚拟医疗模式的应用前景：5年门诊回顾分析
James Luke Douketis,Sam Schulman
James Luke Douketis
Background With a trend toward greater virtual care in selected clinical settings, perioperative anticoagulant management appears well suited for this care delivery model. We explored the potential for virtual care among patients who are re...
Subramanian Senthilkumaran,Ketan Patel,Elanchezhian Rajan et al.
Subramanian Senthilkumaran et al.
Envenomings by Russell's viper ( Daboia russelii ), a species of high medical importance in India and other Asian countries, commonly result in hemorrhage, coagulopathies, necrosis, and acute kidney injury. Although bleeding complications a...
Platelets and the Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus or Antiphospholipid Syndrome [0.03%]
系统性红斑狼疮或抗磷脂综合征患者的血小板和补体 lect2 反应途径激活
Signe Risbøl Vils,Anne Troldborg,Anne-Mette Hvas et al.
Signe Risbøl Vils et al.
Background Patients with systemic lupus erythematosus (SLE) have an increased risk of thrombosis even when they do not have antiphospholipid syndrome (APS). Interactions between complement activation and activated platelets have been sugges...
Identification of High Platelet Reactivity Despite ADP P2Y 12 Inhibitor Treatment: Two Populations in the Vasodilator-Stimulated Phosphoprotein Assay and Variable PFA-P2Y Shapes of Curve [0.03%]
阿司匹林抵抗患者血小板高反应性的血管舒张素刺激磷酸化蛋白检测及不同PFA-P2Y曲线形状的临床意义：来自VSP试验的数据
Cyril Mariethoz,Emmanuelle Scala,Elena Matthey-Guirao et al.
Cyril Mariethoz et al.
Introduction Response to ADP P2Y 12 receptor inhibition by clopidogrel can be evaluated by various techniques. Here, we compared a functional rapid point-of-care technique (PFA-P2Y) with the degree of biochemical inhibition assessed by the ...
Geographical Variation in the Use of Oral Anticoagulation and Clinical Outcomes among Patients with Atrial Fibrillation in Denmark, Sweden, and Finland [0.03%]
丹麦、瑞典和芬兰心房颤动患者口服抗凝药使用率的地域差异及临床转归研究
Lars Frost,Olli Halminen,Mika Lehto et al.
Lars Frost et al.
Background Geographical mapping of variations in the treatment and outcomes of a disease is a valuable tool for identifying inequity. We examined international and intranational variations in initiating oral anticoagulation (OAC) therapy an...
John Raedts,Edwin Kellenbach
John Raedts
Heparin is typically extracted from domestic pigs, which may carry zoonotic adventitious agents. Prion and viral safety cannot be assured by testing the active pharmaceutical ingredient itself; instead for the evaluation of the adventitious...
Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW [0.03%]
未治疗及接受最少治疗的甲型血友病患者的现实世界观察性研究设计：保护 NOW 研究
Johannes Oldenburg,Susan Halimeh,Georgina W Hall et al.
Johannes Oldenburg et al.
Background The efficacy, safety, and immunogenicity of each of Octapharma's factor VIII (FVIII) products, Nuwiq, octanate, and wilate, have been investigated in previously untreated patients (PUPs) with severe hemophilia A in prospective cl...